- About Us
- Nano-Social Network
- Nano Consulting
- My Account
One of Australia's largest investments in a start-up biotechnology company - AUD15 million - has been made with the aim of developing a revolutionary new needle-free vaccine delivery system.
New company Vaxxas Pty Ltd will enable Australian Institute for Bioengineering and Nanotechnology (AIBN) Professor Mark Kendall to continue his pioneering research and development of the Nanopatch.
The investment is led by OneVentures, with co-investors Brandon Capital, the Medical Research Commercialisation Fund (MRCF) and US-based HealthCare Ventures.
The Nanopatch has thousands of small projections designed to deliver the vaccine to abundant immune cells in the skin, whereas the traditional syringe hits the muscle where there are few immune cells.
Early stage testing in animals so far has shown a Nanopatch-delivered flu vaccine is effective with only 1/150th of the dose compared to a syringe and the adjuvants currently required to boost the immunogenicity of vaccines may not be needed.
In addition to improving the efficiency of delivery, the Nanopatch has the potential to dramatically improve patient convenience and reduce the complications associated with needle phobia, needle stick injuries and cross contamination, which are key global health issues.
The Nanopatch is designed for thermostability and to not need refrigeration, making transport much cheaper and easier, particularly to developing nations around the world.
Professor Kendall said in the developed world about 14 per cent of a vaccine's costs were in maintaining the cold chain - while in the developing world the impact was even greater.
"In Africa about half of vaccines aren't working properly because of a breakdown in the cold chain," Professor Kendall said.
"The Nanopatch also offers a way to stop needle-stick injuries during vaccination - which again is a particularly important problem in Africa; with a third of vaccines affected by other complications brought about through cross contamination needle stick injury."
OneVentures General Partner Dr Paul Kelly said the significance of the million investment was not just in its size.
"This investment syndicate includes both local and international investors, which is a real vote of confidence in the Nanopatch approach and an appreciation of the potential of the technology to revolutionise vaccine delivery worldwide," Dr Kelly said.
Dr Kelly will join the Board of Directors of Vaxxas, along with Brandon Capital Partners Managing Director Dr Stephen Thompson; HealthCare Ventures Managing Director Douglas E. Onsi; and UniQuest General Manager of Life Sciences Dr Dean Moss.
The million investment was negotiated by UniQuest Pty Limited, The University of Queensland's main commercialisation company. UniQuest has led the commercialisation of the Nanopatch technology to date, and will hand over the responsibility to Vaxxas following this investment.
Dr Thompson said launching Vaxxas as a company was a critical next step for the Nanopatch technology.
"In Australia, we invest heavily in our excellent research and development capability but have a relatively poor record of taking those technologies to world markets," he said.
"The syndicate's investment in Vaxxas is consistent with its willingness to work with Australia's leading research institutes, including the AIBN, to transform this exciting research effort into a commercially useful product.
"We need to convert the promise of the technology into a reality."
Mr Onsi said the Nanopatch had the potential to transform vaccine delivery for the pharmaceutical industry and for patients around the world.
"HealthCare Ventures searches globally for the most promising innovations in life sciences and we are very pleased to make our first Australian investment in Vaxxas," he said.
About The University of Queensland
The University of Queensland sets its agenda within a truly global context. We are a university that is connected with the global community, addressing the issues that are impacting on our world. Our aim is to attract the best minds of today, and to develop and support the leaders of tomorrow. We have an ongoing commitment to strengthening our impact and reputation by building greater research capacity and through the delivery of high quality teaching and learning programs. We are educating a broad and representative student body and providing them with qualifications relevant to the local and global workforce.
About the Nanopatch
The Nanopatch is a silicone patch with thousands of small projections designed to hit abundant immune cells in the skin. Professor Mark Kendall and his team have tested the Nanopatch and confirmed in animals improved immune responses compared to standard needle and syringe injections. In animals treated with influenza vaccines, the Nanopatch induced immune responses achieved equivalent protection with 1/150th of the delivered dose; which was 10 times better than any other delivery system tested.
Other significant Nanopatch results have been published with the delivery of vaccines for Human Papilloma Virus (HPV), Human Simplex Virus (HSV 2), Chikungunya and West Nile Virus. A vaccine is coated onto the Nanopatch, which could eliminate the need for the vaccines to be refrigerated when they are stored and transported, overcoming a key global challenge for vaccines.
About Professor Mark Kendall
Professor Kendall leads a research team at the Australian Institute for Bioengineering and Nanotechnology (AIBN), developing needle-free delivery of vaccines targeting the skin. He has been working on the Nanopatch for the past eight years. Professor Kendall joined UQ in 2006 as a joint appointment at the AIBN, the Diamantina Institute and the Faculty of Health Sciences. Prior to this, he was a Lecturer in the Department of Engineering Science and Magdalen College at the University of Oxford, UK, and also Associate Director of the PowderJect Centre for Gene and Drug Delivery.
Since returning to Australia, he first secured a Queensland Smart State Senior Fellowship, followed by an Australian Research Council Future Fellowship; which he currently holds. In addition, Professor Kendall's Nanopatch research has been supported by research grants from Queensland's Smart State program, the Australian Research Council (ARC), National Health and Medical Research Council, and the Bill and Melinda Gates Foundation.
About AIBN www.aibn.uq.edu.au
The Australian Institute for Bioengineering and Nanotechnology (AIBN) is an integrated multi-disciplinary research institute bringing together the skills of world-class researchers in the areas of bioengineering and nanotechnology. It is home to 20 research groups working at the interface of biological, chemical and physical science to alleviate problems in human health and environmental issues.
The focus of AIBN's research efforts is on developing new products, processes and devices for improving human health and quality of life. In this way the institute goes beyond basic research to promote and develop the growth of innovative industries, which will benefit the Queensland and Australian economies.
The AIBN acknowledges the financial support of Atlantic Philanthropies, the Queensland State Government and The University of Queensland toward the construction of the million AIBN research facility.
About OneVentures www.one-ventures.com.au
OneVentures is a venture capital firm that invests in emerging Australian technology companies with true breakout potential, differentiated technology and compelling business models in the clean technology, information technology and life sciences sectors. OneVentures is managed by a team of partners with a skills set and track record ideally suited to collaboration with entrepreneurial management teams to foster growth and create value: a unique blend of highly successful entrepreneurs, technology business founders and corporate executives with a strong scientific pedigree, extensive off-shore experience and networks.
The OneVentures Innovation Fund is a million venture capital fund formed as an Early Stage Venture Capital Limited Partnership. OneVentures is supported by the Australian Government through the IIF program with this funding matched by institutional investors, individual high net worth investors and family offices. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies.
About Brandon Capital Partners www.brandoncapital.com.au
Brandon Capital Partners was established in 2007 and makes seed and venture capital investments in emerging businesses in the life science industry. Brandon Capital Partners is passionate about turning good science into improved medical outcomes. The Brandon team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and Brandon's investors.
The million Brandon Biosciences Fund 1 (BBF1) is supported by the Australian Government's IIF program, a venture capital initiative that supports innovation funds and fund managers with expertise in early-stage venture capital investing to commercialise the outcomes of Australia's strong research capability.
About The Medical Research Commercialisation Fund (MRCF) www.mrcf.com.au
The million Medical Research Commercialisation Fund (MRCF) Collaboration is an innovative investment collaboration established in 2007 and managed by Brandon Capital Partners. The MRCF invests in early stage development and commercialisation opportunities emanating from its membership of 30 Australian medical research institutes and allied research hospitals, which includes AIBN.
The MRCF IIF fund is supported by AustralianSuper, StatewideSuper and the Australian Government under its IIF program. The MRCF also acknowledges the support of the state governments of Victoria, New South Wales, Western Australia and Queensland.
About Health Care Ventures www.hcven.com
HealthCare Ventures is a leading global life sciences venture capital firm investing in early stage companies with potential to transform patient care. Since its founding in 1985, HealthCare Ventures has raised billion in nine funds and has invested in over 100 companies, 67 as start-up ventures.
For more information, please click here
Erik de Wit
61 0427 281 466, 3346 3962
Dr Paul Kelly
61 0450 461 824
Copyright © The University of QueenslandIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Explaining how 2-D materials break at the atomic level January 20th, 2017